Abstract 1629MO
Background
WD/DD LPS usually arises in the abdomen, while other LPS subtypes mainly have an extra-abdominal origin. With the lack of prospective data on anthracycline-based CT in advanced WD/DD LPS, we conducted a retrospective analysis of the activity of cytotoxic regimens in patients (pts) with LPS of intrabdominal origin (IA-LPS) who had entered EORTC/STBSG clinical studies, assuming that the vast majority of LPS at this location are WD/DD LPS.
Methods
We searched for all adult pts treated with first-line CT for advanced IA-LPS in EORTC/STBSG phase II-III trials from 1970. Treatment was aggregated into 5 groups: anthracycline (A) alone (Doxorubicin (D) 75 mg/m2, Caelyx 50 mg/m2, Epirubicin 75 mg/m2, Epirubicin 150 mg/m2), Ifosfamide (IFO) alone (IFO 5 g/m2, IFO 9 g/m2, IFO 12 g/m2), D+IFO (D 50 mg/m2+IFO 5 g/m2, D 75 mg/m2+IFO 5 g/m2, DOX 75 mg/m2+IFO 10 g/m2), D+cyclophosphamide+vincristine+DTIC (CYVADIC), “other” (brostallicin, trabectedin). Response was assessed by RECIST or WHO criteria. Progression-free survival (PFS) and overall survival (OS) were computed by Kaplan-Meier method.
Results
109 IA-LPS pts from 13 trials, enrolled between 1978 and 2012, were identified (median age 57 yrs). Overall, there were 10/109 (9.2%) responders to CT: Table: 1629MO
Response | TreatmentN (%) | Total (N=109) | ||||
A alone (N=48) | IFO alone (N=15) | D+IFO (N=18) | CYVADIC (N=8) | Other (N=20) | ||
CR | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
PR | 3 (6.3) | 2 (13.3) | 4 (22.2) | 1 (12.5) | 0 (0.0) | 10 (9.2) |
SD | 24 (50.0) | 10 (66.7) | 5 (27.8) | 4 (50.0) | 14 (70.0) | 57 (52.3) |
PD | 20 (41.7) | 3 (20.0) | 6 (33.3) | 3 (37.5) | 6 (30.0) | 38 (34.9) |
Not evaluable | 1 (2.1) | 0 (0.0) | 3 (16.7) | 0 (0.0) | 0 (0.0) | 4 (3.7) |
At 10-mo median follow-up (IQR 6-24), m-OS was 19 mos (95%CI 15-21), m-PFS 4 mos (95%CI 3-6). D+IFO achieved a not statistically significant longer m-PFS (12 mos) and m-OS (31 mos) than observed with other regimens. Univariate and multivariate analysis of response to CT did not identify prognostic factors.
Conclusions
Cytotoxic CT, in particular D alone, had limited activity in advanced IA-LPS. Though IFO-containing regimens showed higher activity compared to A alone in a small number of cases. This series provides a benchmark for future trials on new drugs in WD/DD LPS.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
EORTC Soft Tissue and Bone Sarcoma Group.
Funding
Has not received any funding.
Disclosure
S. Stacchiotti, B. Kasper: Honoraria (self), Research grant/Funding (institution), Travel/Accommodation/Expenses: Pharmamar. R. Sanfilippo: Research grant/Funding (institution), Travel/Accommodation/Expenses: Pharmamar. All other authors have declared no conflicts of interest.
Resources from the same session
1621MO - Long-term efficacy, tolerability and overall survival in patients (pts) with unresectable or metastatic (U/M) PDGFRA D842V-mutant gastrointestinal stromal tumour (GIST) treated with avapritinib: NAVIGATOR phase I trial update
Presenter: Robin Jones
Session: Mini Oral - Sarcoma
Resources:
Abstract
Slides
Webcast
1622MO - Clinical benefit with ripretinib as ≥4th line treatment in patients with advanced gastrointestinal stromal tumors (GIST): Update from the phase III INVICTUS study
Presenter: John Zalcberg
Session: Mini Oral - Sarcoma
Resources:
Abstract
Slides
Webcast
1623MO - Ripretinib intra-patient dose escalation (IPDE) following disease progression provides clinically meaningful progression-free survival (PFS) in gastrointestinal stromal tumor (GIST) in phase I study
Presenter: Filip Janku
Session: Mini Oral - Sarcoma
Resources:
Abstract
Slides
Webcast
1624MO - Weekly nab-paclitaxel for progressive or symptomatic desmoid tumors: A multicenter single arm phase II trial from the Spanish Group for Research on Sarcoma (GEIS)
Presenter: Javier Martin Broto
Session: Mini Oral - Sarcoma
Resources:
Abstract
Slides
Webcast
1625MO - ABCB1/P-glycoprotein (Pgp) expression as stratification factor for treatment of patients with non metastatic extremity high grade osteosarcoma: An Italian Sarcoma Group (ISG) multicentric prospective trial (ISG/OS-2)
Presenter: Emanuela Palmerini
Session: Mini Oral - Sarcoma
Resources:
Abstract
Slides
Webcast
1626MO - Treatment expectations and preferences for quality versus quantity of life in patients with advanced soft tissue sarcomas starting palliative 1st line chemotherapy
Presenter: Eugenie Younger
Session: Mini Oral - Sarcoma
Resources:
Abstract
Slides
Webcast
1627MO - Systemic therapies in advanced epithelioid haemangioendothelioma (EHE): A retrospective international series from the World Sarcoma Network
Presenter: Anna Maria Frezza
Session: Mini Oral - Sarcoma
Resources:
Abstract
Slides
Webcast
1628MO - A new benchmark for designing phase II trials for advanced or metastatic leiomyosarcoma (LMS) patients using progression free survival (PFS) as primary endpoint – an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) meta-analysis
Presenter: Georgios Kantidakis
Session: Mini Oral - Sarcoma
Resources:
Abstract
Slides
Webcast
Open & welcome
Presenter: Jean-Yves Blay
Session: Mini Oral - Sarcoma
Resources:
Slides
Webcast
Invited Discussant 1621MO, 1622MO and 1623MO
Presenter: Jean-Yves Blay
Session: Mini Oral - Sarcoma
Resources:
Slides
Webcast